Agora Labs

Powering real-time, secure health data sharing at scale with privacy guaranteed for medical research.

Cover Block

Public sources

Field	Detail
Name	Agora Labs
Tagline	Powering real-time, secure health data sharing at scale with privacy guaranteed for medical research. [Agoralabs.eu]
Headquarters	Rome, Italy [Forbes Italia, October 2026]
Founded	2022 [Forbes Italia, October 2026]
Stage	Seed [Forbes Italia, October 2026]
Business model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Growth profile	Venture Scale
Founding team	Davide Zaccagnini and Fabio Giulietto, co-founders [Konsulteer]
Funding label	Seed
Total disclosed funding	$4,600,000 [Forbes Italia, October 2026]

Executive Summary

PUBLIC Agora Labs builds privacy-preserving infrastructure that lets hospitals make clinical data usable for research without moving raw patient data outside the institution, a proposition that is timely because the company disclosed a new €4.3 million seed round in October 2026 and claims a network of 50 international healthcare institutions [Startupbusiness.it, October 2026] [Forbes Italia, October 2026]. The company was founded in Rome in 2022 by Davide Zaccagnini and Fabio Giulietto, and its origin story is more research-led than commercial-first: public reporting says it emerged from a European project on secure clinical-data sharing launched after GDPR took effect in 2018 [Startupbusiness.it, October 2026] [Konsulteer].

The technical wedge, as described in public coverage, is a federated architecture in which an on-premises node with Nvidia GPUs sits inside the hospital, specialized large language models structure and standardize data, and irreversible mathematical anonymization is applied before research use [Startupbusiness.it, October 2026]. That combination matters because it speaks to the central constraint in real-world evidence: access to clinically useful data without creating new data-transfer and consent liabilities, an area where Agora Labs says it operates directly [Forbes Italia, October 2026] [euCanSHare].

The founding team has relevant domain overlap. Zaccagnini is described as a vascular surgeon and biomedical computer scientist trained at MIT, while Giulietto is reported as an engineer with an MBA from Imperial College London; public profiles also identify Zaccagnini as CEO and Giulietto as CTO [Startupbusiness.it, October 2026] [Forbes Italia, October 2026] [The Org].

On financing, the company announced a €4.3 million seed round led by P101 with participation from Infinite Five, the Mussetto family holding, giving Agora Labs fresh capital but still placing it firmly in early execution mode [Forbes Italia, October 2026] [Startupbusiness.it, October 2026]. The business model is B2B, selling infrastructure into healthcare institutions and research workflows, although public materials do not yet provide pricing, contract structure, or revenue disclosure [Agoralabs.eu] [Scalable, October 2026].

What deserves close monitoring over the next 12 to 18 months is less the headline funding and more the quality of commercialization evidence. The reported 50-institution network, including Harvard Medical School and San Raffaele, is encouraging if it converts into repeatable production usage, and management also said it planned to double that network after October 2026, but public reporting does not yet separate pilots, active deployments, and revenue-bearing accounts [Forbes Italia, October 2026].

Lightly corroborated -- The section relies mainly on Forbes Italia and Startupbusiness.it, with partial corroboration from public profiles and company materials.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed, total disclosed ~€4.3 million

How the Company Got Here

PUBLIC The company in view here is the Rome-based health data infrastructure startup, not other businesses that share the Agora Labs name. Agora Labs says it is "powering real-time, secure health data sharing at scale" from Rome, Italy, and the structured research identifies the business as founded in 2022 by Davide Zaccagnini and Fabio Giulietto [Agoralabs.eu] [LinkedIn, retrieved 2026].

The founding context matters because the company appears to have been built out of a specific regulatory and research problem rather than a broad software thesis. According to Agora Labs' public materials, its work sits around secure health data sharing for research, while founder-linked public profiles identify Zaccagnini as Founder and CEO and Giulietto as part of the founding team [Agoralabs.eu] [LinkedIn, retrieved 2026].

The first disclosed financing milestone arrived in October 2026, when Forbes Italia reported a €4.3 million seed round led by P101 with participation from Infinite Five and the Mussetto family [Forbes Italia, October 2026]. That announcement is also the clearest public marker of the company's early scale, with coverage tying Agora Labs to a network of 50 international healthcare institutions at the time of the round [Forbes Italia, October 2026].

Lightly corroborated -- Founding, HQ, and company description are supported by the company website and founder-linked LinkedIn profiles; the financing milestone in this section relies on Forbes Italia [Agoralabs.eu] [LinkedIn, retrieved 2026] [Forbes Italia, October 2026].

Product and Technology

MIXED

The product claim here is straightforward, and unusually specific for an early healthtech company: Agora Labs says it gives hospitals the infrastructure to make clinical data usable for medical and scientific research without moving the underlying patient data out of the hospital environment [Startupbusiness.it, October 2026]. Public coverage describes an architecture built around an on-premises computing node using Nvidia GPUs, with specialized large language models used to structure and standardize clinical data before research use [Startupbusiness.it, October 2026]. The same reporting says the system applies irreversible mathematical anonymization before data is made available downstream, which places the company squarely in privacy-preserving real-world evidence infrastructure rather than a conventional data aggregation model [Startupbusiness.it, October 2026] [Forbes Italia, October 2026].

A second layer of the stack appears to be governance, not only compute. Agora Labs' website describes the company as "powering real-time, secure health data sharing at scale" for healthcare research [Agoralabs.eu]. Separate profile coverage says the platform supports secure, real-time sharing of health data for clinical research and AI purposes, though that claim is closer to company-positioning language than independently tested product evidence [Scalable, October 2026]. One earlier project interview tied co-founder and CEO Davide Zaccagnini to blockchain-mediated data access control and patient consent management, which is useful context for the design philosophy, but it should be read as adjacent evidence rather than a current product specification for the commercial platform [euCanSHare] [Spotify for Creators].

The only visible hiring signals are consistent with a privacy-first data platform. Agora Labs' careers page lists openings in privacy engineering, software engineering, people operations, and finance [agoralabs.eu]. That does not by itself confirm architecture choices, but it supports a reasonable reading that the company is building internal capability around privacy-preserving machine learning and scalable platform software (inferred from job postings) [agoralabs.eu]. The public record does not provide a verified demo, benchmark, or deployment-level technical performance data, so the central product bet still rests on press-reported architecture and company materials rather than independent technical validation [Startupbusiness.it, October 2026] [Agoralabs.eu].

Lightly corroborated -- Product architecture is described in one named press source and supported by company materials, with partial context from secondary profiles and project interviews [Startupbusiness.it, October 2026] [Agoralabs.eu] [Scalable, October 2026] [euCanSHare].

Where the Demand Sits

PUBLIC

The market matters now because hospitals, researchers, and AI developers are all trying to use clinical data more intensively, while privacy law and institutional risk still make raw data movement difficult [Forbes Italia, October 2026] [Startupbusiness.it, October 2026] [Scalable, October 2026].

Agora Labs is positioned around what Forbes Italia describes as the real-world evidence market, a segment built on clinical data generated in routine care rather than controlled trial settings [Forbes Italia, October 2026]. The public record here is narrower than investors would usually want. No named third-party market report in the sourced material provides TAM, SAM, or SOM figures for real-world evidence, federated health data infrastructure, or privacy-preserving clinical AI infrastructure, so any hard market sizing would risk false precision. What is supportable is the demand shape: hospitals hold large volumes of clinically useful data, but the company pitch, repeated across coverage, is that those data can be made available for research without leaving the hospital, which speaks to a real procurement constraint rather than a discretionary feature request [Startupbusiness.it, October 2026] [Startbase, October 2026].

The immediate tailwinds are practical before they are thematic. Startupbusiness.it reports that Agora Labs installs on-premises computing nodes using Nvidia GPUs, then uses specialized large language models to structure and standardize data and applies irreversible anonymization before research use [Startupbusiness.it, October 2026]. That product architecture lines up with two visible sources of demand in the underlying market: first, institutions want research-grade interoperability from messy clinical records; second, they want a way to do that without centralizing raw patient data in a manner that creates added governance friction [Startupbusiness.it, October 2026] [Scalable, October 2026]. Forbes Italia's report that the company had a network of 50 international healthcare institutions as of October 2026, including Harvard Medical School and San Raffaele in Milan, suggests that at least some buyers see value in this model, although that network figure appears in a single publication and should be treated with care [Forbes Italia, October 2026].

The adjacent markets are also material, because this is not only a point solution for data access. On the public evidence, Agora Labs sits at the intersection of real-world evidence, clinical research infrastructure, privacy-preserving machine learning, and health data governance [Forbes Italia, October 2026] [Startupbusiness.it, October 2026] [Scalable, October 2026]. Substitute approaches likely include centralized de-identification pipelines, legacy hospital data warehouses, and narrower consent-management or interoperability tooling, although the sourced material does not name vendors directly. That matters because budget ownership may come from research, IT, innovation, or compliance teams depending on the deployment, and cross-functional selling can lengthen procurement even when the underlying need is clear.

Regulation is less a backdrop here than the market's organizing constraint. Startupbusiness.it says the company emerged from a European research project on secure clinical-data sharing launched after GDPR entered into force in 2018, and euCanSHare links co-founder Davide Zaccagnini to work on blockchain-mediated data access control and patient consent management [Startupbusiness.it, October 2026] [euCanSHare]. In other words, the market is being shaped by the requirement to make health data useful without weakening privacy protections. That tends to favor architectures that keep computation close to the data and make access control auditable, but it also means sales cycles can be slowed by institutional review, security validation, and legal sign-off rather than pure product evaluation.

Cited market-related claim	Detail	Source
Core target market	Real-world evidence market	[Forbes Italia, October 2026]
Primary demand constraint	Clinical data can be used for research while kept inside the hospital	[Startupbusiness.it, October 2026]
Technical deployment model	On-premises Nvidia GPU node at hospital sites	[Startupbusiness.it, October 2026]
Regulatory context	Company emerged from post-GDPR secure data-sharing research project	[Startupbusiness.it, October 2026]

The table shows why the market case is credible even without a clean sizing dataset in the public materials. The demand signal is less about headline market dollars and more about a specific bottleneck: regulated institutions need usable clinical data infrastructure that does not require exporting sensitive records.

Lightly corroborated -- Section relies primarily on Forbes Italia and Startupbusiness.it, with Scalable and euCanSHare providing partial corroboration on market context and regulatory framing.

Competitive Landscape

MIXED Agora Labs is positioned less as a data repository and more as privacy-preserving infrastructure for hospitals that want to contribute clinical data to research without moving raw patient records off site [Startupbusiness.it, October 2026] [Forbes Italia, October 2026].

The public record here is thinner than the product narrative, so the competitive map has to start from category logic rather than a verified roster of named rivals. On one side sit hospital data infrastructure incumbents and research-data platforms that benefit from existing procurement relationships; on another sit newer privacy and federated-learning challengers that sell the promise of computation near the data; and adjacent to both are internal hospital data teams, which remain the default substitute when institutions decide to build controlled research pipes themselves rather than buy them. Agora Labs' disclosed wedge is unusually specific within that field: an on-premises Nvidia GPU node inside the hospital, LLM-based structuring and standardization, and irreversible anonymization before research use [Startupbusiness.it, October 2026].

That specificity matters because it narrows the comparison set. The strongest public evidence suggests the company is competing for institutions that are constrained less by willingness to share data than by governance, privacy, and cross-site interoperability concerns [Startupbusiness.it, October 2026] [Forbes Italia, October 2026]. In that frame, the relevant alternatives are not simply other AI health startups, but any stack that can satisfy hospital compliance teams, clinical researchers, and technical administrators at the same time. The fact pattern also points to real-world evidence as the commercial lane, which usually rewards trust, repeatability, and institutional references more than rapid feature expansion [Forbes Italia, October 2026].

Where Agora Labs appears to have an edge today is in product-design alignment with hospital risk tolerance. Keeping data inside the hospital, installing local compute, and applying anonymization before research use are not just technical choices, they are adoption arguments in a GDPR-shaped market [Startupbusiness.it, October 2026]. The reported network of 50 international healthcare institutions, including Harvard Medical School and San Raffaele in Milan, is the clearest public signal that this argument is landing beyond pilot theory, although that figure comes from funding coverage and should be treated carefully until corroborated elsewhere [Forbes Italia, October 2026]. If accurate, the early network can compound: each institutional deployment may strengthen references, workflow know-how, and trust with future sites. At the same time, this edge looks perishable if larger vendors package similar privacy-preserving workflows into products hospitals already buy, because Agora does not appear from the public record to control a dominant distribution channel or a proprietary data asset outside the installed network.

The company is most exposed where category leaders can turn compliance credibility and procurement reach into faster rollout. Nvidia is named as a technology partner supplying GPUs for the on-premises nodes, which supports the architecture but also suggests dependence on external infrastructure rather than a hardware or model moat owned outright by Agora Labs [Startupbusiness.it, October 2026]. Internal hospital IT and research informatics teams are another meaningful substitute: for large academic centers, building a narrower in-house pipeline may be slower but can be politically easier than adopting a new vendor across departments. Public materials also do not establish a broad ecosystem hold, such as payer distribution, national health-system channel ownership, or a regulator-endorsed standard, which limits the evidence for a winner-take-most dynamic in the next 18 months.

The most plausible near-term scenario is a sorting between specialist infrastructure providers that can turn privacy architecture into repeatable deployments and general-purpose data vendors that remain strong but less tailored to cross-institution research workflows. In that scenario, Agora Labs is a winner if hospitals continue to prefer local-control architectures for research-grade data use and if the reported 50-institution network converts into denser referenceability across Europe and selected international sites [Forbes Italia, October 2026] [Startupbusiness.it, October 2026]. The likely loser if procurement shifts the other way is the internal build path, because bespoke hospital projects tend to weaken when an external platform can satisfy privacy constraints with less implementation burden. The reverse also holds: Agora Labs would be the one under pressure if large incumbent health IT vendors make on-premises, privacy-first research data sharing a standard module inside existing enterprise contracts.

Lightly corroborated -- Competitive analysis relies on company coverage from Forbes Italia and Startupbusiness.it,

Opportunity

Upside Case

PUBLIC The prize here is straightforward: if Agora Labs becomes trusted infrastructure for privacy-preserving clinical research across major hospital systems, it could sit at the control point between fragmented health data and the institutions that want to use that data for real-world evidence and AI development [Forbes Italia, October 2026] [Startupbusiness.it, October 2026].

The headline opportunity is to become a default data-access layer for hospitals that want to participate in research without moving raw patient data outside their walls [Startupbusiness.it, October 2026]. That outcome is still early, but not purely aspirational. The public record shows a Rome-based company founded in 2022, a disclosed €4.3 million seed round led by P101 in October 2026, and a reported network of 50 international healthcare institutions that includes Harvard Medical School and San Raffaele in Milan [Forbes Italia, October 2026]. The product architecture also points at a real wedge rather than a generic software pitch: on-premises Nvidia GPU nodes inside hospitals, large language models for structuring clinical data, and irreversible anonymization before research use [Startupbusiness.it, October 2026]. In a market where data governance is often the bottleneck, infrastructure that lets hospitals keep control while still contributing to research is a credible route to strategic relevance [Forbes Italia, October 2026] [Startupbusiness.it, October 2026].

Scenario	What happens	Catalyst	Why it's plausible
Hospital network standard	Agora Labs becomes the preferred infrastructure layer for a widening group of European and international hospitals participating in research collaborations	The reported plan to double a 50-institution network after October 2026 converts into visible network expansion and reference deployments [Forbes Italia, October 2026]	The company already reported a 50-institution network and cites named institutions, while its architecture is designed to keep data within hospitals, which addresses a core adoption constraint [Forbes Italia, October 2026] [Startupbusiness.it, October 2026]
Real-world evidence rail	The platform becomes a recurring access and workflow layer for real-world evidence studies run by hospitals and research partners	Broader adoption of privacy-preserving research infrastructure as real-world evidence programs scale inside health systems [Forbes Italia, October 2026]	Agora Labs is explicitly positioned in the real-world evidence market, and its product is built around making clinical data usable for medical and scientific research without centralizing raw records [Forbes Italia, October 2026] [Startupbusiness.it, October 2026]
AI-ready clinical data backbone	Agora Labs becomes an embedded preprocessing and governance layer for AI development on hospital data	Demand for structured, standardized, privacy-preserved data rises as health systems pursue AI use cases and research collaborations [Scalable, October 2026] [Startupbusiness.it, October 2026]	The company says it uses specialized large language models to structure and standardize data, and public profiles describe it as enabling secure, real-time sharing for research and AI purposes [Startupbusiness.it, October 2026] [Scalable, October 2026]

What compounding looks like is less about consumer-style network effects and more about institutional trust, deployment repetition, and workflow lock-in. Each hospital node installed on premises creates a local technical footprint, and each successful research workflow can make the next institutional conversation easier because the privacy posture is already part of the product narrative [Startupbusiness.it, October 2026]. If the reported 50-institution network is directionally accurate, that matters because a hospital considering adoption is not evaluating a blank-sheet startup, but a system that has already been accepted by other medical institutions, including recognized names cited in coverage [Forbes Italia, October 2026]. The careers page also suggests the company is staffing for the pieces that support compounding, including privacy engineering, software, people, and finance, which is consistent with moving from prototype deployments toward a more repeatable operating model [agoralabs.eu, Unknown].

The size of the win is difficult to quantify from public evidence because no verified market-size figure or directly comparable public peer is included in the source set. Still, a concrete upside case can be stated narrowly. If the "hospital network standard" scenario plays out, Agora Labs could become a strategic infrastructure asset in European health data exchange and research enablement, with value driven by its position in workflow, compliance-sensitive deployment, and institutional relationships rather than by model IP alone (scenario, not a forecast) [Forbes Italia, October 2026] [Startupbusiness.it, October 2026]. The evidence base does not support a defensible valuation range in public, but it does support the claim that the company is pursuing a control point that, if won, would matter far beyond a typical seed-stage software vendor.

Lightly corroborated -- This section relies primarily on Forbes Italia and Startupbusiness.it, with supplemental company careers-page evidence; several material operating claims remain single-source or company-adjacent.

Sources